Complete financial analysis of TMS Co., Ltd. (4891.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TMS Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- SABB Takaful Company (8080.SR) Income Statement Analysis – Financial Results
- Shenzhen Zowee Technology Co., Ltd. (002369.SZ) Income Statement Analysis – Financial Results
- Scottish Re Group Limited (SKRUF) Income Statement Analysis – Financial Results
- Xinjiang Sayram Modern Agriculture Co., Ltd (600540.SS) Income Statement Analysis – Financial Results
- Da-Cin Construction Co.,Ltd. (2535.TW) Income Statement Analysis – Financial Results
TMS Co., Ltd. (4891.T)
About TMS Co., Ltd.
TMS Co., Ltd. engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities. The company is developing TMS-007, a stachybotrys microspora triprenyl phenol (SMTP) congener with prothrombolytic and anti-inflammatory/antioxidative activities, which has completed Phase 2a clinical trials for acute ischemic stroke treatment; and TMS-008, an SMTP congener with anti-inflammatory/antioxidative activities under nonclinical development for inflammatory complications, such as acute kidney injury and cancer cachexia. It is also developing TMS-009, a product candidate in preclinical development. The company has a collaboration with Hokkaido University and Kanazawa University to evaluate the potential of the drug candidate compounds as novel drugs, as well as a joint research agreement with Teikyo University to identify biomarkers for renal function and a strategic alliance with Ji Xing Pharmaceuticals Limited. TMS Co., Ltd. was incorporated in 2005 and is headquartered in Fuchu, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 1.95B | 0.00 |
| Cost of Revenue | 6.95M | 6.60M | 201.66M | 4.09M |
| Gross Profit | -6.95M | -6.60M | 1.74B | -4.09M |
| Gross Profit Ratio | 0.00% | 0.00% | 89.64% | 0.00% |
| Research & Development | 607.73M | 297.90M | 304.28M | 603.24M |
| General & Administrative | 335.53M | 222.25M | 506.61M | 117.92M |
| Selling & Marketing | -22.53M | 0.00 | 0.00 | 0.00 |
| SG&A | 313.00M | 222.25M | 506.61M | 117.92M |
| Other Expenses | 23.00M | -627.00K | 155.00K | 605.00K |
| Operating Expenses | 943.25M | 520.15M | 810.88M | 721.16M |
| Cost & Expenses | 943.25M | 520.15M | 810.88M | 721.16M |
| Interest Income | 42.00K | 89.00K | 77.00K | 102.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 6.95M | 6.60M | 737.00K | 4.09M |
| EBITDA | -937.00M | -854.88M | 1.08B | -717.89M |
| EBITDA Ratio | 0.00% | 0.00% | 63.27% | 0.00% |
| Operating Income | -943.25M | -520.15M | 1.14B | -721.16M |
| Operating Income Ratio | 0.00% | 0.00% | 58.34% | 0.00% |
| Total Other Income/Expenses | -15.84M | -341.32M | -56.33M | -826.00K |
| Income Before Tax | -959.09M | -861.47M | 1.08B | -721.98M |
| Income Before Tax Ratio | 0.00% | 0.00% | 55.45% | 0.00% |
| Income Tax Expense | 950.00K | -545.00K | 2.45M | 950.00K |
| Net Income | -960.04M | -860.93M | 1.08B | -722.93M |
| Net Income Ratio | 0.00% | 0.00% | 55.32% | 0.00% |
| EPS | -26.02 | -25.28 | 53.36 | -20.89 |
| EPS Diluted | -26.02 | -25.28 | 53.36 | -20.89 |
| Weighted Avg Shares Out | 36.90M | 34.05M | 20.18M | 34.60M |
| Weighted Avg Shares Out (Dil) | 36.90M | 34.05M | 20.18M | 34.60M |
Source: https://incomestatements.info
Category: Stock Reports